To study the genome-wide contribution of Ddx5 and Ddx17 to the androgen-signaling pathway, we applied the same experimental strategy using the human LNCaP prostate cancer cell line that was treated with DHT for 24 h (Figure 4A). This evidence concerns the gene DDX5 and prostate carcinoma.